You searched for "Immunotherapy"

210 results found

Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high-risk UTUC

High-risk upper tract urothelial carcinoma (UTUC) has been associated with poor survival outcomes. The authors evaluated the role of neoadjuvant chemotherapy in high-risk cases prior to radical nephroureterectomy (RNU) in terms of pathological stage of the final surgical specimen. A...

One cycle of adjuvant chemotherapy in tumours of the testis

Following a radical orchiectomy, current UK practice for newly diagnosed, high-risk, stage 1 nonseminomatous or combined germ cell tumours of the testis (NSCGCTT) is either two cycles of adjuvant chemotherapy with bleomycin, etoposide, cisplatin (BE360Px2) or surveillance with BE500Px3 on...

My experience of addiction

In this incredibly honest and thought-provoking article, we hear from an anonymous doctor who has struggled with addiction. The nature of addiction is a subject of interest to a broad range of scientific disciplines, from medicine to psychology, psychotherapy and...

Onco-fertility: a review

Subfertility or infertility is a major problem affecting men diagnosed with testicular cancer (TC) either due to the disease itself [1], or as a result of management [2]. TC is the most prevalent cancer affecting men of reproductive age [3]....

The Welsh Urological Society (WUS)

By Thomas Ellul, Specialist Registrar in Urology, Wales Deanery. The New Year brings with it the opportunity for urologists in Wales to congregate and discuss the events of the previous year as well as current research, guidelines and hot topics....

Can we make LATE-presenting posterior urethral valves an EARLIER-treated condition?

What are posterior urethral valves? Posterior urethral valve (PUV) is the most common cause of congenital bladder outlet obstruction (BOO) and renal failure in male children. They were first described by the Italian anatomist Giovanni Battista Morgagni back in the...

Testicular cancer: management of stage I seminoma

Introduction Testicular cancer is the most frequently occurring solid tumour in men between the ages of 15 and 34 years [1]. About 60% of cases are seminomas and approximately 70-80% of them have, at presentation, clinical stage I disease. This...

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy

There is increasing evidence for the role of radical prostatectomy in select patients with T3-T4 prostate cancer (as part of multimodal therapy). This retrospective multicentre study explored the benefit of neoadjuvant hormonal therapy before radical prostatectomy specifically in patients with...

Read all about it Jul/Aug 2014

It can be awkward when a patient asks you about a report in their favourite tabloid detailing an amazing research breakthrough or a ‘cutting-edge’ new treatment / test and you don’t know what they are talking about! So this section...

Management of stage 1 non-seminomatous germ cell tumours

Testicular cancer (TC) is the most successfully treated solid tumour, achieving a cure rate of 90-95% [1-3]. Testicular cancer is relatively rare with an incidence of 2207 cases in the UK in 2014 [4] and yet is the most common...

The role of specialist therapeutic radiographers in the treatment and care of men with prostate cancer

The Statement of Intent: Cancer Strategy for England: 2015-2020 indicates that the number of people diagnosed with cancer each year will continue to grow rapidly due to the ageing population. There is also a requirement to diagnose and offer patients...

ICS 2019 Standards (two-volume set)

The highly anticipated fully updated 2019 edition of the International Continence Society (ICS) Standards is a comprehensive ‘book’ that compiles peer-reviewed documents into one easily accessible area of 935 pages. It has taken the joint effort and expertise of over...